Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis

Joint Bone Spine

Volumn 82, Issue 1, 2015, Pages 25-30

  Pers, Yves Marie ^a   Schaub, Roxane ^b   Constant, Elodie ^c   Lambert, Joseph ^d   Godfrin Valnet, Marie ^e   Fortunet, Clémentine ^f   Bourichi, Waafa ^a   Prades, Béatrice Pallot ^c   Wendling, Daniel ^e   Gaudin, Philippe ^d   Jorgensen, Christian ^a   Maillefert, Jean Francis ^f   Marotte, Hubert ^c  

^a LAPEYRONIE HOSPITAL   (France)

^b Montpellier 1 University   (France)

^c UNIVERSITÉ JEAN MONNET   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Drug survival; Efficacy; Elderly; Rheumatoid arthritis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; PEPTIDE ANTIBODY; RHEUMATOID FACTOR; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACROCYANOSIS; ACUTE HEPATITIS; ADULT; ADVERSE OUTCOME; AGED; ANAPHYLACTIC SHOCK; ARTICLE; CELLULITIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DIVERTICULITIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYSIPELAS; FEMALE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HELMINTHIASIS; HEPATITIS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMONIA; PULMONARY HYPERTENSION; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SINUSITIS; SKIN ALLERGY; TREATMENT RESPONSE; VOMITING; ARTHRITIS, RHEUMATOID; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922114220     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.07.010     Document Type: Article

References (26)

1. Tutuncu Z., Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am 2007, 33:57-70.
2. Boots A.M., Maier A.B., Stinissen P., et al. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol 2013, 9:604-613.
3. Widdifield J., Bernatsky S., Paterson J.M., et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res 2013, 65:353-361.
4. Bathon J.M., Fleischmann R.M., Van der Heijde D., et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006, 33:234-243.
5. Koller M.D., Aletaha D., Funovits J., et al. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology 2009, 48:1575-1580.
6. Ornetti P., Chevillotte H., Zerrak A., et al. Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients. Drugs Aging 2006, 23:855-860.
7. Radovits B.J., Kievit W., Fransen J., et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1470-1473.
8. Dahl S.L., Samuelson C.O., Williams H.J., et al. Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy 1990, 10:79-84.
9. Soubrier M., Tatar Z., Couderc M., et al. Rheumatoid arthritis in the elderly in the era of tight control. Drugs Aging 2013, 30:863-869.
10. Koike T., Harigai M., Inokuma S., et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011, 70:2148-2151.
11. EMA EMARoActemra (tocilizumab). Summary of Product Characteristics 2014, Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf (Accessed 04 February).
12. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
13. Pham T., Claudepierre P., Constantin A., et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010, 77:S3-S100.
14. Smolen J.S., Landewe R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
15. van Gestel A.M., Prevoo M.L., van't Hof M.A., et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40.
16. Prevoo M.L., van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
17. Smolen J.S., Landewe R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
18. Gibbons L.J., Hyrich K.L. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 2009, 23:111-124.
19. Genevay S., Finckh A., Ciurea A., et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007, 57:679-685.
20. Yamanaka H., Tanaka Y., Inoue E., et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011, 21:122-133.
21. Pers Y.M., Fortunet C., Constant E., et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology 2014, 53:76-84.
22. Sakai R., Tanaka M., Nanki T., et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 2012, 71:1820-1826.
23. Bannwarth B., Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011, 10:123-131.
24. Campbell L., Chen C., Bhagat S.S., et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011, 50:552-562.
25. Radovits B.J., Fransen J., van Riel P.L., et al. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis 2008, 67:1127-1131.
26. Smolen J.S., Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011, 63:43-52.